🇺🇸 Angiotensin-Converting Enzyme Inhibitor in United States

102 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Completed Suicide — 28 reports (27.45%)
  2. Death — 12 reports (11.76%)
  3. Hypotension — 11 reports (10.78%)
  4. Toxicity To Various Agents — 10 reports (9.8%)
  5. Coronary Revascularisation — 9 reports (8.82%)
  6. Renal Failure Acute — 9 reports (8.82%)
  7. Poisoning — 7 reports (6.86%)
  8. Cardiac Arrest — 6 reports (5.88%)
  9. Renal Failure — 5 reports (4.9%)
  10. Respiratory Arrest — 5 reports (4.9%)

Source database →

Angiotensin-Converting Enzyme Inhibitor in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Angiotensin-Converting Enzyme Inhibitor approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Angiotensin-Converting Enzyme Inhibitor in United States?

Brigham and Women's Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.